Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China.
Department of Pediatrics, The Fifth People's Hospital of Ji'nan, Jinan, China.
Thorac Cancer. 2018 Sep;9(9):1180-1184. doi: 10.1111/1759-7714.12823. Epub 2018 Jul 30.
This study was conducted to explore the influence of clinical features of rhabdomyosarcoma (RMS) and a refined therapeutic protocol on the therapeutic efficacy and prognosis in children in the past five years.
Forty children diagnosed with RMS were retrospectively studied, using a version of the therapeutic protocol refined by Shanghai Children's Medical Center (version 2009.9.1). The patients' demographic characteristics, clinical manifestations, pathological features, therapeutic efficacy, and prognosis were analyzed.
Of the 40 children, 17 abandoned treatment. Of the remaining 23 cases, two children were rated as low risk, 12 as medium risk, and nine as high risk, and all received treatment. Patients in the low and medium-risk groups had better prognosis than those in the high-risk group, and treated patients had higher survival rates and longer survival than untreated patients.
Children with RMS should be treated positively. Combined treatment shows better therapeutic efficacy and prognosis. The refined therapeutic protocol seems more effective than the standard treatment, with a significant impact on long-term RMS prognosis.
本研究旨在探讨横纹肌肉瘤（RMS）的临床特征和改良治疗方案对过去五年儿童治疗效果和预后的影响。
回顾性研究了 40 例经上海儿童医学中心改良治疗方案（2009.9.1 版）诊断为 RMS 的患儿。分析了患儿的人口统计学特征、临床表现、病理特征、治疗效果和预后。
40 例患儿中，17 例放弃治疗。在其余 23 例患儿中，2 例为低危，12 例为中危，9 例为高危，均接受了治疗。低危和中危组患儿的预后优于高危组，且治疗组患儿的生存率和生存时间均高于未治疗组。
RMS 患儿应积极治疗。联合治疗显示出更好的治疗效果和预后。改良治疗方案似乎比标准治疗更有效，对 RMS 的长期预后有显著影响。
